Eversight Academy has curated this free on-demand training to help you best serve your patients. Let us help you seamlessly adopt BrightMEM for anterior keratoplasty.

BrightMEM by Brightstar Therapeutics is a durable, acellular Descemet’s membrane with proliferative proteins. It forms a new foundation for the ocular surface, protecting the stroma from degradation, promoting regeneration of the corneal epithelium and optimizing limbal stem cell growth. 

BrightMEM offers novel treatment for limbal stem cell deficiency (LSCD) and complex ocular surface disease (OSD). Patients living with these complex disease states often present with comorbidities, suffer poor vision and experience chronic eye pain and discomfort. 

BrightMEM anterior keratoplasty (DMAK) is a simple on-lay procedure utilizing the decellularized corneal graft. The optically clear graft helps form a new foundation for the ocular surface while also reducing pain. 

Preclinical data show limbal stem cell and epithelium support and protection from stromal melting. Early clinical results demonstrate re-epithelization without any serious tissue-related adverse reactions.